SLCO1B1 A388G가 스타틴에 의한 지질감소 효과 및 근육독성 발생에 미치는 영향: 체계적 문헌고찰 및 메타분석

키워드

참고문헌 (59)

1. van Rooy MJ, "Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events", Curr Med Chem, 21(19), pp.2121~2129 (2014)
2. Last AR, "Hyperlipidemia : Drugs for Cardiovascular Risk Reduction in Adults", Am Fam Physician, 95(2), pp.78~87 (2017)
3. Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
4. "Korean Statistical Information Service"[URL]
5. "Disease statistics"[URL]
6. Karlson BW, "Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C : Results from the VOYAGER meta-analysis", Eur J Prev Cardiol, 23(7), pp.744~747 (2016)
7. Silverman MG, "Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions : A Systematic Review and Meta-analysis", JAMA, 316(12), pp.1289~1297 (2016)
8. Kopin L, "Dyslipidemia", Ann Intern Med, 167(11), pp.ITC81~ITC96 (2017)
9. Mihaylova B, "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials", Lancet, 380(9841), pp.581~590 (2012)
10. "BIT Druginfo"[URL]
11. Jones PH, "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses(STELLAR*Trial)", Am J Cardiol, 92(2), pp.152~160 (2003)
12. Kapur NK, "Clinical efficacy and safety of statins in managing cardiovascular risk", Vasc Health Risk Manag, 4(2), pp.341~353 (2008)
13. Ridker PM, "Percent reduction in LDL cholesterol following highintensity statin therapy : potential implications for guidelines and for the prescription of emerging lipid-lowering agents", Eur Heart J, 37(17), pp.1373~1379 (2016)
14. Stancu C, "Statins : mechanism of action and effects", J Cell Mol Med, 5(4), pp.378~387 (2001)
15. Yamashita S, "Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions", J Atheroscler Thromb, 17(5), pp.436~451 (2010)
16. Ridker PM, "Clinical application of C-reactive protein for cardiovascular disease detection and prevention", Circulation, 107(3), pp.363~369 (2003)
17. Tousoulis D, "Innate and adaptive inflammation as a therapeutic target in vascular disease : the emerging role of statins", J Am Coll Cardiol, 63(23), pp.2491~2502 (2014)
18. Ridker PM, "Creactive protein levels and outcomes after statin therapy", N Engl J Med, 352(1), pp.20~28 (2005)
19. Schaefer EJ, "Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects", Am J Cardiol, 95(9), pp.1025~1032 (2005)
20. Tietge UJ, "Hyperlipidemia and cardiovascular disease : inflammation, dyslipidemia, and atherosclerosis", Curr Opin Lipidol, 25(1), pp.94~95 (2014)
21. Alfirevic A, "Phenotype standardization for statininduced myotoxicity", Clin Pharmacol Ther, 96(4), pp.470~476 (2014)
22. Feng Q, "Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions", Pharmacogenomics, 13(5), pp.579~594 (2012)
23. Lee HH, "Interindividual and interethnic variability in drug disposition : polymorphisms in organic anion transporting polypeptide 1B1(OATP1B1; SLCO1B1)", Br J Clin Pharmacol, 83(6), pp.1176~1184 (2017)
24. Oshiro C, "PharmGKB very important pharmacogene : SLCO1B1", Pharmacogenet Genomics, 20(3), pp.211~216 (2010)
25. Nagy A, "Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations", BMC Genet, 16(1), pp.108~ (2015)
26. Mwinyi J, "Evidence for inverse effects of OATP-C(SLC21A6)5and 1b haplotypes on pravastatin kinetics", Clin Pharmacol Ther, 75(5), pp.415~421 (2004)
27. Maeda K, "Effects of organic anion transporting polypeptide 1B1haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril", Clin Pharmacol Ther, 79(5), pp.427~439 (2006)
28. Romaine SP, "The influence of SLCO1B1(OATP1B1)gene polymorphisms on response to statin therapy", Pharmacogenomics J, 10(1), pp.1~11 (2010)
29. Choi JH, "Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans", Clin Pharmacol Ther, 83(2), pp.251~257 (2008)
30. Dai R, "Association between SLCO1B1 521 T C and 388 A G Polymorphisms and Statins Effectiveness : A Meta-Analysis", J Atheroscler Thromb, 22(8), pp.796~815 (2015)
31. Jiang J, "Association between SLCO1B1-521T C and-388A G polymorphisms and risk of statin-induced adverse drug reactions : A meta-analysis", Springerplus, 5(1), pp.1368~ (2016)
32. Pasternak RC, "ACC", AHA, J Am Coll Cardiol, pp.2002, 40(3)[DOI]
33. de Lemos JA, "Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes : phase Z of the A to Z trial", JAMA, 292(11), pp.1307~1316 (2004)
34. "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"[URL]
35. Zheng JS, "Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: metaanalysis of data from 21 independent prospective cohort studies", BMJ, 346, pp.f3706~ (2013)
36. 이소연, "비타민 D 농도와 신생아 조기 패혈증의 연관성에 대한 체계적 문헌고찰 및 메타분석", 한국임상약학회지, 28(1), pp.10~16 (2018), 한국임상약학회[DOI]
37. Zhang BB, "Association between the MDR1 gene variant C3435T and risk of leukaemia : a metaanalysis", Eur J Cancer Care(Engl), 22(5), pp.617~625 (2013)
38. Huedo-Medina TB, "Assessing heterogeneity in meta-analysis : Q statistic or I2index?", Psychol Methods, 11(2), pp.193~206 (2006)
39. Couvert P, "Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy", Pharmacogenomics, 9(9), pp.1217~1227 (2008)
40. Yang GP, "Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients", Acta Pharmacol Sin, 31(3), pp.382~386 (2010)
41. Rodrigues AC, "Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A G variant is determinant of increased atorvastatin response", Int J Mol Sci, 12(9), pp.5815~5827 (2011)
42. Akao H, "Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly", Atherosclerosis, 220(2), pp.413~417 (2012)
43. Sortica VA, "SLCO1B1 gene variability influences lipidlowering efficacy on simvastatin therapy in Southern Brazilians", Clin Chem Lab Med, 50(3), pp.441~448 (2012)
44. Shabana MF, "Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia", Mol Diagn Ther, 17(5), pp.299~309 (2013)
45. Giannakopoulou E, "No impact of SLCO1B1 521T C, 388A G and 411G A polymorphisms on response to statin therapy in the Greek population", Mol Biol Rep, 41(7), pp.4631~4638 (2014)
46. Meyer zu Schwabedissen HE, "Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort", Pharmacogenet Genomics, 25(1), pp.8~18 (2015)
47. Prado Y, "SLCO1B1 c.388A G Polymorphism is associated with HDL-C Levels in response to atorvastatin in chilean individuals", Int J Mol Sci, 16(9), pp.20609~20619 (2015)
48. Kaewboonlert N, "Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients", J Clin Pharm Ther, 43(5), pp.647~655 (2018)
49. Santos PC, "SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia", Eur J Clin Pharmacol, 68(3), pp.273~279 (2012)
50. Hu M, "Intronic variants in SLCO1B1 related to statininduced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia", Pharmacogenet Genomics, 22(11), pp.803~806 (2012)
51. Lee HK, "Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9", 19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients, 2013, pp.14(11), 1283~1294
52. Donnelly LA, "Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2diabetes : a go-DARTS study", Clin Pharmacol Ther, 89(2), pp.210~216 (2011)
53. Mirosevic Skvrce N, "ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions : a case-control study", Pharmacogenomics, 16(8), pp.803~815 (2015)
54. Liu JE, "SLCO1B1 521T C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients : a nested case-control study", Eur J Clin Pharmacol, 73(11), pp.1409~1416 (2017)
55. Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25 Pt B)[DOI]
56. Thompson JF, "An association study of 43 SNPs in 16 candidate genes with atorvastatin response", Pharmacogenomics J, 5(6), pp.352~358 (2005)
57. Morrone D, "Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response : a pooled analysis of over 21, 000subjects from 27 clinical trials", Atherosclerosis, 223(2), pp.251~261 (2012)
58. Kullak-Ublick GA, "Organic anion-transporting polypeptide B(OATP-B)and its functional comparison with three other OATPs of human liver", Gastroenterology, 120(2), pp.525~533 (2001)
59. Knauer MJ, "Human skeletal muscle drug transporters determine local exposure and toxicity of statins", Circ Res, 106(2), pp.297~306 (2010)

관련 논문AI추천